Best way to switch osteoporosis meds after denosumab? small study tests timing
NCT ID NCT04177940
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 45 people with osteoporosis caused by long-term steroid use. Participants had stopped taking denosumab and were switched to either zoledronic acid or alendronate at different times. The goal was to see which timing and drug best controlled bone loss markers. Results may guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- denosumab, zoledronic acid, alendronate
- What this could lead to
- If successful, this could help doctors choose the best follow-up treatment to prevent bone loss after stopping denosumab in people on long-term steroids.
- What could go wrong
- This is a small pilot study with only 45 participants, so results may not apply to everyone. The study measures bone turnover markers, not actual fractures, so real-world benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-INDUCED OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?